{"id":1018033,"date":"2026-11-05T22:59:56","date_gmt":"2026-11-06T03:59:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"modified":"2026-11-05T22:59:56","modified_gmt":"2026-11-06T03:59:56","slug":"aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","title":{"rendered":"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>DOYLESTOWN, Pa., Nov.  05, 2026  (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and meet with investors\u00a0at Guggenheim\u2019s 3rd Annual Healthcare Innovation Conference, to be held November 9-11, 2026 in Boston, MA.<\/p>\n<p>\n        <strong>Presentation Details<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%\">Date:<\/td>\n<td style=\"max-width:80%;width:80%;min-width:80%\">Monday, November 9, 2026<\/td>\n<\/tr>\n<tr>\n<td>Time:\u00a0<\/td>\n<td>10:00 am ET<\/td>\n<\/tr>\n<tr>\n<td>Webcast link:<\/td>\n<td>Click <a href=\"https:\/\/event.summitcast.com\/view\/oVDtKqmPn2tPc7VV7WsLAC\/guest_book?session_id=JA2HznBofRBRn9HZuwxuph\" rel=\"nofollow\" target=\"_blank\">here<\/a><\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>Those interested in arranging a one-on-one meeting with Dr. Gilad should contact their Guggenheim representative.<\/p>\n<p>\n        <strong>About Aprea<\/strong>\n      <\/p>\n<p>Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea\u2019s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company\u2019s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9R5G2mMDhtTgsdxZSptQmUmiGb8wwKDh0MtonXZHldDoX8ZhYYmAuYOpmVAZNRxO-xYEUBUrgvQEjoLXBVNxKg==\" rel=\"nofollow\" target=\"_blank\"><u>www.aprea.com<\/u><\/a>.<\/p>\n<p>The Company may use, and intends to use, its investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p9m0d4muJvV7O84p3z-jIw-EdpcsOdjuVK3kpr8NmaahosfHbn5mXlWCWCbBjUKk6IUdPjQyO80oHVazi_2Gv1wIpaa8w7h5gX1AMR1EU40=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/ir.aprea.com\/<\/u><\/a> as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.<\/p>\n<p>\n        <strong>Investor and Media Contact:<br \/><\/strong>Mike Moyer<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=65Ynx8hnpsOlwlmJIzBzSCd9Bto6ivROh9p4gl9S-ya8NQOl8k5IcqzITFkGtxRyfTh94uKpuBO4yQKWuQ_ZcOZ50Y67IM8lOn_CeV5DTv4AajoAk_prhtOdEsr2_ytB\" rel=\"nofollow\" target=\"_blank\"><u>mmoyer@lifesciadvisors.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Sean Naughton Ph.D.<br \/>Russo Partners, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T3rP3vudNYQxJj1bl2C75Q6qHltRM9aMmYYEhj9ZpVkgZuFUU3sYXRfrVQv95trjVTtZB_hVHFDSUcxGtQXngZcslmKmUsqZKTiwTTt226XtuG5n2UWO1iHFijId7-qHfqdnYPol_c6AdKNUvpsJjfpNmVOqLQ_j5uNaJKxMWD3wMYRp9RFJEYhCAT7nLxczuB2vHOpr2Ul6m2qK8HCEOiFdWoNOgMLDRXjwAeFfvA1MqPv04fWJxHd4p1vq4z_bGhhDoPmqpr-RC65ztzw-U6Ork1zJ9BQo8of_FLmdig7MCfvjI7jkL9OM1EmC14IJ5C1DAKRTSivObosXteti_Q==\" rel=\"nofollow\" target=\"_blank\">sean.naughton@russopartnersllc.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTc0YmI4MzMtODQyOC00ODY1LTk1MmUtMTE3ZWE5MjdkMTYyLTExOTI4NDktMjAyNi0xMS0wNS1lbg==\/tiny\/Aprea-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and meet with investors\u00a0at Guggenheim\u2019s 3rd Annual Healthcare Innovation Conference, to be held November 9-11, 2026 in Boston, MA. Presentation Details Date: Monday, November 9, 2026 Time:\u00a0 10:00 am ET Webcast link: Click here \u00a0 \u00a0 Those interested in arranging a one-on-one meeting with Dr. Gilad should contact their Guggenheim representative. About Aprea Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018033","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and meet with investors\u00a0at Guggenheim\u2019s 3rd Annual Healthcare Innovation Conference, to be held November 9-11, 2026 in Boston, MA. Presentation Details Date: Monday, November 9, 2026 Time:\u00a0 10:00 am ET Webcast link: Click here \u00a0 \u00a0 Those interested in arranging a one-on-one meeting with Dr. Gilad should contact their Guggenheim representative. About Aprea Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated &hellip; Continue reading &quot;Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T03:59:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference\",\"datePublished\":\"2026-11-06T03:59:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"wordCount\":285,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"name\":\"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=\",\"datePublished\":\"2026-11-06T03:59:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","og_description":"DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and meet with investors\u00a0at Guggenheim\u2019s 3rd Annual Healthcare Innovation Conference, to be held November 9-11, 2026 in Boston, MA. Presentation Details Date: Monday, November 9, 2026 Time:\u00a0 10:00 am ET Webcast link: Click here \u00a0 \u00a0 Those interested in arranging a one-on-one meeting with Dr. Gilad should contact their Guggenheim representative. About Aprea Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated &hellip; Continue reading \"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-06T03:59:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference","datePublished":"2026-11-06T03:59:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"wordCount":285,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","name":"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=","datePublished":"2026-11-06T03:59:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTczNyM3OTQ5NzY3IzIxODEyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018033"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018033\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}